HALO Stock Rises 36% in a Month: Here's What You Should Know

Shares of Halozyme Therapeutics HALO have risen 36.4% in the past month, primarily driven by growing investor confidence in its novel drug-delivery technology, ENHANZE, which enables the subcutaneous (“SC”) administration of drugs. Earlier this month, the company reported robust second-quarter 2026 results and raised its full-year 2026 financial outlook, further boosting investor sentiment and contributing to the recent share-price gain.

Halozyme has collaboration agreements with large pharma companies, which use its ENHANZE technology for the development of SC formulations of their various approved drugs.

Per the agreements, these companies have been granted worldwide license rights to develop and commercialize their products using ENHANZE technology. These deals generate royalties on sales of marketed drugs, milestone payments and annual license fees, which comprise Halozyme’s top line.

Halozyme has several marketed partnered drugs based on the ENHANZE technology, including the SC formulation of J&J’s JNJ Darzalex, argenx’s ARGX Vyvgart Hytrulo and Roche’s Phesgo.

Year to date, shares of Halozyme have rallied 57.7% compared with the industry’s rise of 13.8%.

Image Source: Zacks Investment Research

Halozyme Banks on Higher Royalties

Halozyme’s top line currently comprises product sales, royalty payments, as well as revenues under collaboration agreements related to its ENHANZE technology with some large pharma companies.

The company’s total revenues in the first half of 2026 were primarily driven by higher royalty payments from J&J for SC Darzalex, as well as argenx for Vyvgart Hytrulo.

HALO’s revenues from royalties rose 46.7% year over year to $373.8 million during the first half of 2026.

Halozyme has two commercial proprietary products, Hylenex and Xyosted. Incremental sales from these products also boosted Halozyme’s revenues during the first half of 2026. Total product sales increased 63% year over year to $260.1 million during this period.

Reflecting the strong business performance, Halozyme raised its full-year 2026 financial outlook. The company now expects 2026 revenues of $1.84-$1.91 billion, up from its previous guidance of $1.71-$1.81 billion.

Meanwhile, royalty revenues are now anticipated in the range of $1.22-$1.25 billion compared with the earlier projection of $1.13-$1.17 billion.

Halozyme’s recent business developments and continued growth in royalty revenues from partners are expected to support top-line growth and strengthen its long-term growth outlook. These catalysts could provide further support to the stock’s positive momentum.

HALO's Zacks Rank & Another Key Pick

Halozyme currently carries a Zacks Rank #2 (Buy).

A top-ranked stock in the biotech sector is Repligen RGEN, currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Over the past 60 days, estimates for Repligen’s 2026 earnings per share have risen from $1.99 to $2.06, while estimates for 2027 have increased from $2.57 to $2.61 during the same time. RGEN’s shares have gained 10% year to date.

Repligen’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 16.80%.

Beyond Nvidia: AI's Second Wave Is Here

The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research